Evidence map›Paper›PMID 37006315›Full record

ArticleFrontiers in immunology2023

Antibody response in children with multisystem inflammatory syndrome related to COVID-19 (MIS-C) compared to children with uncomplicated COVID-19.

Anaïs Thiriard, Benjamin Meyer, Christiane S Eberhardt, Natasha Loevy, Serge Grazioli, Wafae Adouan, Paola Fontannaz, Fabienne Marechal, Arnaud G L'Huillier, Claire-Anne Siegrist and 5 more

Open access · goldFull text read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Anaïs ThiriardInstitute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium.
Benjamin MeyerCentre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Christiane S EberhardtCentre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Natasha LoevyPediatric Platform for Clinical Research, Department of Woman, Child and Adolescent Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Serge GrazioliDivision of Neonatal and Pediatric Intensive Care, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Wafae AdouanCentre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Paola FontannazCentre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Fabienne MarechalPediatric Platform for Clinical Research, Department of Woman, Child and Adolescent Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Arnaud G L'HuillierPediatric Infectious Diseases Unit, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Claire-Anne SiegristCentre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Daphnée GeorgesInstitute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium.
Antonella PutignanoInstitute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium.
Arnaud MarchantInstitute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium.
Arnaud M DidierlaurentCentre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Geraldine Blanchard-RohnerCentre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
University of Geneva · CHUniversité Libre de Bruxelles · BEUniversity Hospital of Geneva · CHUniversity of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To comprehensively analyze the quality of the antibody response between children with Multisystem inflammatory syndrome (MIS-C) and age-matched controls at one month after SARS-CoV-2 exposure, and infected in the same time-period. Methods: Serum from 20 MIS-C children at admission, and 14 control children were analyzed. Antigen specific antibody isotypes and subclasses directed against various antigens of SARS-CoV-2 as well as against human common coronavirus (HCoVs) and commensal or pathogenic microorganisms were assessed by a bead-based multiplexed serological assay and by ELISA. The functionality of these antibodies was also assessed using a plaque reduction neutralization test, a RBD-specific avidity assay, a complement deposition assay and an antibody-dependent neutrophil phagocytosis (ADNP) assay. Results: Children with MIS-C developed a stronger IgA antibody response in comparison to children with uncomplicated COVID-19, while IgG and IgM responses are largely similar in both groups. We found a typical class-switched antibody profile with high level of IgG and IgA titers and a measurable low IgM due to relatively recent SARS-CoV-2 infection (one month). SARS-CoV-2-specific IgG antibodies of MIS-C children had higher functional properties (higher neutralization activity, avidity and complement binding) as compared to children with uncomplicated COVID-19. There was no difference in the response to common endemic coronaviruses between both groups. However, MIS-C children had a moderate increase against mucosal commensal and pathogenic strains, reflecting a potential association between a disruption of the mucosal barrier with the disease. Conclusion: Even if it is still unclear why some children develop a MIS-C, we show here that MIS-C children produce higher titers of IgA antibodies, and IgG antibodies with higher functionality, which could reflect the local gastro-intestinal mucosal inflammation potentially induced by a sustained SARS-CoV-2 gut infection leading to continuous release of SARS-CoV-2 antigens.

Indexed as

Blood Group AntigensConnective Tissue DiseasesCOVID-19Antibodies, ViralAntibody FormationChildHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MSARS-CoV-2Systemic Inflammatory Response SyndromeAntibodies, ViralBlood Group AntigensImmunoglobulin AImmunoglobulin GImmunoglobulin Mantibody responsecommensalscommon coronavirusfunctional antibodyMIS-C multisystem inflammatory syndrome in childrenSARS-CoV-2

Identifiers

PMID37006315
PMCPMC10050384
OpenAlexW4324376171

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read74
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.